Cara Therapeutics Announces Positive Topline Data From Phase 2 Trial of Oral KORSUVA™ in Chronic Kidney Disease Patients with Moderate-to-Severe Pruritus
Cara Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing new chemical entities.
Read More